1 week Ago By ABMN Staff
StockNews.com started coverage on shares of Cytosorbents ( NASDAQ:CTSO – Get Free Report ) in a note issued to investors on Friday. The brokerage set a “hold” rating on the medical research company’s stock.
A number of other research firms have also recently weighed in on CTSO. D. Boral Capital reaffirmed a “buy” rating and set a $10.
00 price objective on shares of Cytosorbents in a research report on Tuesday, April 1st. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research report on Thursday, April 3rd.
Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Cytosorbents presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.
67. Check Out Our Latest Analysis on CTSO Cytosorbents Price Performance Cytosorbents ( NASDAQ:CTSO – Get Free Report ) last released its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.
03) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.04.
Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%.
The business had revenue of $9.20 million for the quarter, compared to the consensus estimate of $10.09 million.
Equities research analysts expect that Cytosorbents will post -0.3 EPS for the current year. Institutional Trading of Cytosorbents Several institutional investors have recently made changes to their positions in CTSO.
Millennium Management LLC purchased a new stake in Cytosorbents during the 4th quarter valued at approximately $30,000. Key Client Fiduciary Advisors LLC boosted its position in shares of Cytosorbents by 127.0% during the first quarter.
Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock worth $78,000 after acquiring an additional 43,900 shares during the last quarter. Renaissance Technologies LLC grew its stake in Cytosorbents by 10.6% during the fourth quarter.
Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after acquiring an additional 8,400 shares in the last quarter. Northern Trust Corp increased its holdings in Cytosorbents by 22.3% in the 4th quarter.
Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after acquiring an additional 16,701 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Cytosorbents during the 4th quarter valued at about $99,000.
Hedge funds and other institutional investors own 32.87% of the company’s stock. Cytosorbents Company Profile ( Get Free Report ) Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally.
Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. Read More Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter .
.
